has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of metastatic bladder or urinary tract cancer.

In urothelial bladder cancer, increased T cell infiltration ... the response rate reported was 23% with PD-L1 inhibitor, ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

MIBC is an advanced form of bladder cancer, where the tumor has spread ... III trial looking at the efficacy of the immunotherapy atezolizumab vs. placebo in patients with high-risk MIBC.

Keytruda is already approved for adjuvant treatment after resection and platinum-based chemotherapy for stage IB-IIIA NSCLC, as is Roche’s Tecentriq (atezolizumab), with a similar indication ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Opens in a new tab or window Jazz Pharmaceuticals announced that adding lurbinectedin (Zepzelca) to atezolizumab (Tecentriq ... in non-muscle invasive bladder cancer, including complete responses ...

There are many treatment options for bladder cancer, which vary depending on the stage and type of bladder cancer you have, your overall health, and your preferences. These include various types ...

Metastatic urothelial cancer exhibits substantial molecular heterogeneity compared with the primary tumour, complicating the development of accurate biomarkers. Pre-treatment metastatic biopsies ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...